Pfizer has announced plans to present more than 50 abstracts at this year's American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
During the conference from June 2nd to 6th, the company will share research data covering more than 15 clinical-stage assets across solid and haematologic tumors, encompassing 12 mechanisms of action in total.
“Pfizer will be presenting data on more than 15 clinical-stage cancer assets at this year's annual meeting of the American Society of Clinical Oncology.“
These will include a presentation detailing the performance of the investigational compound dacomitinib in locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations, which will be featured in the official ASCO press programme.
Other abstracts will offer insights into treating lung, breast, kidney and prostate cancers and haematologic malignancies using a variety of marketed and investigational Pfizer therapies, including immuno-oncology and combinations therapies.
Liz Barrett, global president and general manager of Pfizer Oncology, said: "Through our cutting-edge science and a desire to work collaboratively, Pfizer Oncology continues to break boundaries in cancer care and is helping to redefine life with cancer."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical